Sertindole | Lu 23-174 | 5-HT/DA Receptor Antagonist | AmBeed-信号通路专用抑制剂

首页 / / / / Sertindole/舍吲哚

Sertindole/舍吲哚 {[allProObj[0].p_purity_real_show]}

货号：A495787 同义名： Lu 23-174

Sertindole是一种神经安定剂，是一种抗精神病药，具有较高的亲和力，能与多巴胺 D2、血清素 5-HT2A、5-HT2C 和 α1-肾上腺素受体结合。

Sertindole/舍吲哚化学结构
CAS号：106516-24-9

Sertindole/舍吲哚 3D分子结构
CAS号：106516-24-9

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	1周咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Sertindole/舍吲哚纯度/质量文件产品仅供科研

货号：A495787 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Science, 2025, 387(6729): eadp5637. Ambeed. [ A875019 ]; • Nat. Electron., 2025, 8, 66-74. Ambeed. [ A100095 ]; • Adv. Mater., 2025, 2416621. Ambeed. [ A255324 , A420052 ]; • Adv. Mater., 2025, 2410493. Ambeed. [ A838608 ]; • Adv. Mater., 2025, 2420319. Ambeed. [ A106129 ]; 更多 >

多巴胺受体亚型比较

产品名称	D1 receptor ↓ ↑	D2 receptor ↓ ↑	D3 receptor ↓ ↑	D4 receptor ↓ ↑	D5 receptor ↓ ↑	DAT ↓ ↑	Dopamine receptor ↓ ↑	其他靶点	纯度
Penfluridol	+ Dopamine receptor, Ki: 1.6 μM								98%
Ansofaxine HCl	++ Dopamine receptor, IC50: 491 nM								99%
Tetrahydroberberine		+ D2 receptor, pKi: 6.08							98+%
Prochlorperazine Maleate		✔							98% (HPLC)
Olanzapine		✔							99+%
Trifluoperazine		++++ Dopamine D2 receptor, IC50: 1.1 nM							98%
Ropinirole HCl		++ D2 receptor, Ki: 29 nM							99%
Lurasidone		++++ D2 receptor, Ki: 1 nM							98%
Levosulpiride		✔							99+%
Pridopidine		✔							95%
Metoclopramide		✔					✔		99+%
Molindone HCl		✔							99%
Sulpiride		✔							99+%
Perospirone		++++ D2 receptor, Ki: 1.4 nM							99%
Perospirone HCl		++++ D2 receptor, Ki: 1.4 nM							99%
Phenothiazine		✔							98%
Pimozide	+ Dopamine D1 receptor, Ki: 6600 nM	+++ Dopamine D2 receptor, Ki: 3.0 nM	++++ Dopamine D3 receptor, Ki: 0.83 nM						98%
Rotundine	++ D1 receptor, IC50: 166 nM	+ D2 receptor, IC50: 1.47 μM	+ D3 receptor, IC50: 3.25 μM						98%
Domperidone		✔							99+%
ONC206		✔							99%
Pimethixene maleate	++ Dopamine D1 Receptor, pKi: 6.37	+++ Dopamine D2 Receptor, pKi: 8.19		++ Dopamine D4.4 Receptor, pKi: 7.54					97%
Loxapine succinate	++ D2 receptor (Human), Ki: 62 nM D1 receptor (human), Ki: 26 nM	++ D2 receptor (human), Ki: 24 nM D2 receptor (bovine), Ki: 26 nM		+++ D4 receptor (human), Ki: 7.5 nM					98%
Chlorprothixene	+++ D1 receptor, Ki: 18 nM	+++ D2 receptor, Ki: 2.96 nM	+++ D3 receptor, Ki: 4.56 nM		+++ D5 receptor, Ki: 9 nM				99%
SCH-23390 HCl	++++ D1 dopamine receptor, Ki: 0.2 nM				++++ D5 dopamine receptor, Ki: 0.3 nM				98%
MPP+ iodide						✔			97%
σ1 Receptor antagonist-1						+ DAT, pKi: 5.8			97%
Benztropine mesylate						++ DAT, IC50: 118 nM			98%
Azaperone							✔		98%
Ziprasidone HCl							✔		98+%
Paliperidone							✔		98%
Alizapride HCl							✔		99+%
Amisulpride							✔		98%
Quetiapine hemifumarate							✔	Adrenergic Receptor	98%
Clozapine N-oxide							✔		99%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Sertindole/舍吲哚生物活性

描述

Sertindole, a neuroleptic, is one of the antipsychotic medications available. Sertindole exerts a potent antagonism at serotonin 5-HT2A, 5-HT2C, dopamine D2, and αl adrenergic receptors^[3]. Sertindole is at least as effective as haloperidol and risperidone against the positive symptoms of schizophrenia, while it appears superior against negative symptoms. Sertindole is associated with a low rate of extrapyramidal side effects, lacks sedative properties, and may induce a moderate weight gain^[4]. The incidence of QTc interval prolongation of 500 ms or greater with therapeutic dosages of sertindole has also been low. Unlike other antipsychotic agents, sertindole has not been associated with cognitive impairment, and can actually improve cognitive function^[5]. Long-term treatment with sertindole was safe and well tolerated, and patients showed clinical improvement beyond acute treatment^[6].

Sertindole/舍吲哚临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02307396	Schizophrenia ... 展开 >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 收起 <<
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... 展开 >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD 收起 <<

Sertindole/舍吲哚参考文献

[1]Juruena MF, de Sena EP, et al. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85.

[2]Murdoch D, Keating GM. Sertindole : a review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-55.

[3]Juruena MF, de Sena EP, de Oliveira IR. Sertindole in the management of schizophrenia. J Cent Nerv Syst Dis. 2011 May 17;3:75-85

[4]Spina E, Zoccali R. Sertindole: pharmacological and clinical profile and role in the treatment of schizophrenia. Expert Opin Drug Metab Toxicol. 2008 May;4(5):629-38

[5]Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs. 2004;18 Suppl 2:19-30; discussion 41-3

[6]Hale AS, Azorin JM, Lemming OM, Mæhlum E. Sertindole in the long-term treatment of schizophrenia. Int Clin Psychopharmacol. 2012 Jul;27(4):231-7

Sertindole/舍吲哚实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.34mL

2.27mL

1.13mL

22.68mL

4.54mL

2.27mL

Sertindole/舍吲哚技术信息

CAS号	106516-24-9
分子式	C₂₄H₂₆ClFN₄O
分子量	440.94
SMILES Code	FC1=CC=C(N2C3=CC=C(Cl)C=C3C(C4CCN(CCN5CCNC5=O)CC4)=C2)C=C1
MDL No.	MFCD00867749

别名	Lu 23-174
运输	蓝冰
InChI Key	GZKLJWGUPQBVJQ-UHFFFAOYSA-N
Pubchem ID	60149

存储条件

In solvent -20°C:3-6个月-80°C:12个月

Pure form Sealed in dry, 2-8°C

溶解方案

细胞实验：

DMSO: 25 mg/mL(56.7 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验：请根据您的动物给药指南选择适当的溶解方案。
以下溶解方案都请先按照体外实验的方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

方案二

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT02374567	Dementia Depr... 展开 >>ession Schizophrenia Psychosomatic Disorders Anxiety Disorders 收起 <<	Phase 3	Terminated	-	Germany ... 展开 >> Bezirkskrankenhaus Augsburg Augsburg, Germany Krankenhaus Hedwigshöhe Berlin, Germany Hannover Medical School Hannover, Germany, 30625 Asklepios Fachklinikum Lübben Lübben, Germany Asklepios Fachklinikum Teupitz Teupitz, Germany 收起 <<
NCT02307396	Schizophrenia ... 展开 >> Schizophrenia and Disorders With Psychotic Features Schizoaffective Disorders 收起 <<	Phase 4	Completed	-	Germany ... 展开 >> Psychiatrische Klinik und Poliklinik fuer Psychiatrie und Psychotherapie der Technischen Universitaet Muenchen am Klinikum rechts der Isar Munich, Bavaria, Germany, 81675 收起 <<
NCT01765829	Psychosis Nos/Other	Phase 3	Unknown	November 2015	Spain ... 展开 >> Mental Health Unit Villamartín Recruiting Villamartín, Cádiz, Spain, 11650 Contact: José María Mongil San Juan, MD 0034956040209 cheman45@gmail.com Principal Investigator: José María Mongil San Juan, MD Mental Health Unit Baza Recruiting Baza, Granada, Spain, 18800 Contact: Eva Bravo Barba, MD eva.bravo.barba@gmail.com Principal Investigator: Eva Bravo Barba, MD Mental Health Unit Motril Recruiting Motril, Granada, Spain, 18600 Contact: María Luisa Barrigón Estévez, MD 0034958038849 marial.barrigon.sspa@juntadeandalucia.es Principal Investigator: María Luisa Barrigón Estévez, MD Mental Health Unit Andújar Recruiting Andújar, Jaén, Spain, 23740 Contact: Fernando Sarramea Crespo, MD, PhD 0034953021717 fernandosarramea@hotmail.com Principal Investigator: Farnando Sarramea Crespo, MD, PhD Mental Health Unit Martos Recruiting Martos, Jaén, Spain, 23600 Contact: Miguel Ortigosa Luque, MD migueortigosa@hotmail.com Principal Investigator: Miguel Ortigosa Luque, MD Mental Health Unit Miraflores Not yet recruiting Alcobendas, Madrid, Spain, 28100 Contact: María Luisa Zamarro Arraz, MD, PhD 0034916530108 zamarroluisa@yahoo.es Principal Investigator: María Luisa Zamarro Arraz, MD, PhD Hospital Infanta Sofía Not yet recruiting San Sebastian de los Reyes, Madrid, Spain, 28702 Contact: María Rosario Gutiérrez Labrador, MD rosagutierrez@psiquiatra.e.telefonica.net Principal Investigator: María Rosario Guitiérrez Labrador, MD Mental Health Unit Valle del Guadalhorce Not yet recruiting Cártama, Málaga, Spain, 29580 Contact: Daniel Gutiérrez Castillo, MD 0034951033931 dgutierrezcastillo@gmail.com Principal Investigator: Daniel Gutiérrez Castillo, MD Mental Health Unit Las Lagunas Not yet recruiting Fuengiróla, Málaga, Spain, 29650 Contact: María Isabel Osuna Carmona, MD maribelosunac@hotmail.com Principal Investigator: María Isabel Osuna Carmona, MD Fundación Argibide Not yet recruiting Pamplona, Navarra, Spain, 31007 Contact: Ignacio Mata Pastor, MD, PhD 0034948266650 nacho.mata70@gmail.com Principal Investigator: Ignacio Mata Pastor, MD, PhD Hospital El Tomillar Recruiting Dos Hermanas, Seville, Spain, 41700 Contact: Joaquín Carlos Martín Muñoz, MD, PhD 0034955016083 joaquinmartin@hotmail.com Principal Investigator: Joaquín Carlos Martín Muñoz, MD, PhD Hospital Francesc de Borja Recruiting Gandía, Valencia, Spain, 46700 Contact: María Lacruz Silvestre, MD, PhD maria.lacruz.silvestre@gmail.com Principal Investigator: María Lacruz Silvestre, MD, PhD Hospital de Basurto Not yet recruiting Bilbao, Spain, 48013 Contact: Sonia Bustamante Madariaga, MD, Phd 0034944 006137 sonia.bustamantemadariaga@osakidetza.net Principal Investigator: Sonia Bustamante Madariaga, MD, PhD Mental Health Unit Tetuán Not yet recruiting Madrid, Spain, 28003 Contact: Mariano Hernández Monsalve, MD, PhD 0034915347363 hergoico@gmail.com Contact: Ruth Berdún Pe, MD ruthberdun@yahoo.es Principal Investigator: Mariano Hernández Monsalve, MD, PhD Lafora Hospital Not yet recruiting Madrid, Spain, 28049 Contact: Juan Dios Molina Martín, MD, PhD jmolinamar@hotmail.com Principal Investigator: Juan Dios Molina Martín, MD, PhD Hospital Carlos Haya Recruiting Málaga, Spain, 29009 Contact: Fermín Mayoral Cleríes, Md, PhD fermin.mayoral.sspa@juntadeandalucia.es Principal Investigator: Fermín Mayoral Cleríes, MD, PhD Virgen del Rocío Hospital Recruiting Seville, Spain, 41013 Contact: Clara M. Rosso Fernández, MD 0034955013414 claram.rosso.sspa@juntadeandalucia.es Contact: Miguel Ruiz Veguilla, MD, PhD 0034955013414 mruizveguilla@yahoo.com Principal Investigator: Miguel Ruiz Veguilla, MD, PhD 收起 <<
NCT02435095	Schizophrenia	Phase 4	Recruiting	April 2019	Germany ... 展开 >> RWTH University Hospital Aachen Recruiting Aachen, NRW, Germany, 52074 Contact: Sabrina Schaffrath saschaffrath@ukaachen.de Contact: Sarah Lammertz slammertz@ukaachen.de Alexianer Aachen GmbH Not yet recruiting Aachen, Germany, 52062 Zentrum für Neurologie und Seelische Gesundheit im Kapuziner Karree Aachen Not yet recruiting Aachen, Germany, 52062 Contact: Frank Bergmann, Dr. med. LVR Klinik Bonn Recruiting Bonn, Germany, 53111 LVR Klinik Düren Not yet recruiting Düren, Germany, 52353 Klinik und Poliklinik für Psychiatrie und Psychotherapie der Heinrich-Heine-Universität Düsseldorf Recruiting Düsseldorf, Germany, 40629 LVR Klinik Essen Not yet recruiting Essen, Germany, 45147 ViaNobis Gangelt Recruiting Gangelt, Germany, 52538 Klinik Königshof (Abteilung für Allgemeine Psychiatrie) Recruiting Krefeld, Germany, 47807 LVR Klinik Langenfeld Recruiting Langenfeld, Germany, 40764 LVR Klinik Viersen Not yet recruiting Viersen, Germany, 41749 收起 <<
NCT00629252	Schizophrenia	Not Applicable	Terminated(Not enough subjects... 展开 >> have been recruited in the expected period.) 收起 <<	-	Switzerland ... 展开 >> University Hospital of Psychiatry, Department Neuropsychopharmacology and Brain Imaging Zurich, ZH, Switzerland, CH-8032 收起 <<
NCT00612079	Healthy	Not Applicable	Completed	-	Switzerland ... 展开 >> University of Psychiatry Hospital Zurich, ZH, Switzerland, CH-8032 收起 <<
NCT00759460	Schizophrenia	Phase 3	Completed	-	China ... 展开 >> CN002 Beijing, China, 100083 收起 <<
NCT00759421	Schizophrenia	Phase 3	Completed	-	Taiwan ... 展开 >> TWN001 Tapei, Taiwan, 112 收起 <<
NCT00654706	Schizophrenia ... 展开 >> Cognition 收起 <<	Phase 3	Completed	-	United States, California ... 展开 >> US017 Garden Grove, California, United States, 92845 US008 National City, California, United States, 91950 US001 Pasadena, California, United States, 91107 US006 Pico Rivera, California, United States, 90660 US011 San Diego, California, United States, 92126 US014 Stanford, California, United States, 94305 US026 Torrance, California, United States, 90502 United States, Colorado US016 Aurora, Colorado, United States, 80045 United States, Florida US015 Orange City, Florida, United States, 32763 US010 Tampa, Florida, United States, 33613 United States, Georgia US007 Atlanta, Georgia, United States, 30308 United States, Illinois US024 Chicago, Illinois, United States, 60640 US002 Joliet, Illinois, United States, 60435 United States, Maryland US012 Baltimore, Maryland, United States, 21204 US027 Glen Burnie, Maryland, United States, 21061 United States, New Hampshire US019 Lebanon, New Hampshire, United States, 03756 United States, New Jersey US021 Clementon, New Jersey, United States, 08021 United States, New York US013 Brooklyn, New York, United States, 11203 US025 Staten Island, New York, United States, 10305 United States, North Carolina US005 Charlotte, North Carolina, United States, 28211 US018 Durham, North Carolina, United States, 27705 United States, Pennsylvania US022 Philadelphia, Pennsylvania, United States, 19139 United States, Texas US023 Austin, Texas, United States, 78754 US020 Dallas, Texas, United States, 75235 US004 Desoto, Texas, United States, 75115 US028 Houston, Texas, United States, 77008 收起 <<
NCT00885690	Schizophrenia	Not Applicable	Terminated(Due to recruitment ... 展开 >>problems) 收起 <<	-	Denmark ... 展开 >> Aalborg Psychiatric Hospital Aalborg, Denmark, 9000 Sweden Universitets Allmänna Sjukhuset, Malmø UMAS Malmø, Sweden 收起 <<
NCT00345982	Schizophrenia	Not Applicable	Completed	-	Denmark ... 展开 >> Aalborg Psychiatric Hospital Aalborg, Denmark, 9000 收起 <<
NCT00763438	Schizophrenia	Phase 4	Completed	-	France ... 展开 >> FR002 Allonnes, France, 72703 收起 <<
NCT00856583	Schizophrenia	Phase 3	Completed	-	-
NCT02021201	Schizophrenia	Phase 4	Terminated(No suitable patient... 展开 >>s could be recruited in the available time period) 收起 <<	-	Denmark ... 展开 >> Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Psychiatric Center Glostrup Glostrup, Denmark, DK-2600 收起 <<
NCT00480844	Schizophrenia	Phase 4	Unknown	-	Israel ... 展开 >> Department of Psychiatry of the Sheba Medical Center Recruiting Ramat Gan, Tel Hashomer, Israel, 52621 Contact: Mark Weiser, Dr 03-5303773 mweiser@netvision.net.il Principal Investigator: Mark Weiser, Dr Beer-Yaakov Mental Health Center Not yet recruiting Beer-Yaakov, Israel, 70350 Principal Investigator: Yehuda Abramowitz, Dr Kfar Shaul Mental Health Center Not yet recruiting Jerusalem, Israel, 91060 Principal Investigator: Alexander Teitelbaum, Dr 收起 <<
NCT00864045	Schizophrenia	Phase 3	Completed	-	China ... 展开 >> CN001 Beijing, China, 300074 收起 <<
NCT01498770	-		Completed	-	-
NCT00856583	-		Completed	-	-

Sertindole/舍吲哚 {[allProObj[0].p_purity_real_show]}

Sertindole/舍吲哚纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Sertindole/舍吲哚质控信息

Sertindole/舍吲哚生物活性

Sertindole/舍吲哚临床研究

Sertindole/舍吲哚参考文献

Sertindole/舍吲哚实验方案

Sertindole/舍吲哚技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Sertindole/舍吲哚 {[allProObj[0].p_purity_real_show]}

Sertindole/舍吲哚 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Sertindole/舍吲哚 质控信息

Sertindole/舍吲哚 生物活性

Sertindole/舍吲哚 临床研究

Sertindole/舍吲哚 参考文献

Sertindole/舍吲哚 实验方案

Sertindole/舍吲哚 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Sertindole/舍吲哚纯度/质量文件产品仅供科研

Sertindole/舍吲哚质控信息

Sertindole/舍吲哚生物活性

Sertindole/舍吲哚临床研究

Sertindole/舍吲哚参考文献

Sertindole/舍吲哚实验方案

Sertindole/舍吲哚技术信息